Cover Image

Combination of low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical hodgkin lymphoma (rrhl), 5-year experience from tata memorial centre

Saved in:

Bibliographic Details
Main Authors:	Aditya Narayan (Author), Shyam Srinivasan (Author), Poonam Khemani (Author), Nidhi Dhariwal (Author), Akanksha Chichra (Author), Chetan Dhamne (Author), Nirmalya Roy Moulik (Author), Gaurav Narula (Author), Sneha Shah (Author), Tanuja Seth (Author), VikramjitKhanwar (Author), Shripad Banavalli (Author)
Format:	Book
Published:	Elsevier, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcome of pediatric relapsed refractory Hodgkin lymphoma experience from Tata Memorial Hospital , Mumbai
by: Ankita Pandey, et al.
Published: (2022)

Digital India for pediatric acute lymphoblastic leukemia (ALL): Tracking reports during maintenance phase using a web-based application
by: Subham Kumar, et al.
Published: (2024)

Treatment and long-term follow-up of children with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Experience from the Tata Memorial Hospital pediatric CML cohort over 2 decades
by: Nirmalya Roy Moulik, et al.
Published: (2022)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
by: Rudolf Weide
Published: (2008)

Asparginase associated pancreatitis in children with Pre-B-Acute lymphoblastic leukaemia (ALL): A six-year retrospective study from
by: Poonam Khemani, et al.
Published: (2022)

Candidemia in pediatric cancer patients contributes to significant morbidity and mortality: A single centre experience from India
by: P. Khemani, et al.
Published: (2022)

candidemia in pediatric cancer patients contributes to significant morbidity andmortality: A single centre experience from India
by: Khemani Poonam, et al.
Published: (2022)

Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
by: James E, et al.
Published: (2021)

Apoptotic colopathy following bendamustine therapy
by: Vincent Czerwinski, et al.
Published: (2023)

Herpetic esophagitis following bendamustine-containing regimen
by: Yamane H, et al.
Published: (2016)

Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma
by: Brenda Cristie Edina, et al.
Published: (2022)

Painful, plantar nodules in cutaneous macroglobulinosis: Successful treatment with rituximab and bendamustine
by: Carmine D'Acunto, PhD, et al.
Published: (2020)

Perforating folliculitis secondary to bendamustine-rituximab chemotherapy: A case report
by: Rowan Monteiro, et al.
Published: (2017)

Stability of Bendamustine Solutions: Influence of Sodium Chloride Concentration, Temperature and Container
by: Vigneron Jean, et al.
Published: (2018)

Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine-Rituximab
by: Wulyo Rajabto, et al.
Published: (2024)

Pediatric plasmablastic lymphoma - Ten years experience in a tertiary care centre in India
by: Nirmalya Pradhan, et al.
Published: (2016)

Aspectos farmacológicos do anticorpo monoclonal (Nivolumab) utilizando a Via PD-1 no tratamento antitumoral do Linfoma de Hodgkin
by: Fernanda Alves da SILVA, et al.
Published: (2019)

Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
by: Jun Ma, et al.
Published: (2023)

Childhood Hodgkin Lymphoma (hl): single centre experience from eastern India
by: ADITI SHARMA, et al.
Published: (2022)

Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL): Early outcomes
by: Bhavin Visariya, et al.
Published: (2016)

Immunisation in children with cancer treated with standard dose chemotherapy- review of evidence
by: Nirmalya Roy Moulik, et al.
Published: (2020)

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
by: Dan Li, et al.
Published: (2024)

Sorafenib and Everolimus for paediatric patients with unresectable osteosarcoma
by: Shilpa Vijayasrinivasan, et al.
Published: (2017)

Photosensitive rash induced by nivolumab
by: Francisco J. Navarro-Triviño, et al.
Published: (2022)

Nivolumab-Induced Thyroid Dysfunction
by: Lohit Kumbar, et al.
Published: (2021)

Pharmacovigilance Evaluation of Bendamustine-related Skin Disorders using the Japanese Adverse Drug Event Report Database
by: Mayako Uchida, et al.
Published: (2021)

Supportive care in paediatric oncology during the pandemic : Lessons from a nationwide survey
by: Maya Prasad, et al.
Published: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Nivolumab-associated cutaneous T-cell lymphoma
by: Jennifer A. Marks, MD, et al.
Published: (2021)

Umbilical lichen planus induced by nivolumab
by: Luisa Martos-Cabrera, et al.
Published: (2023)

Clinical profile and outcome of classical Hodgkin lymphoma treated with ABVD protocol at Homi Bhabha Cancer Hospital Varanasi
by: NIKITA SINGH, et al.
Published: (2022)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022)

Inverse lichenoid drug eruption associated with nivolumab
by: Lauren M. Guggina, MD, et al.
Published: (2017)

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
by: Edouard Chasseuil, et al.
Published: (2018)

Nivolumab associated vasculopathy: A novel mechanism
by: Adeeb Haroon, MS, et al.
Published: (2022)

Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia
by: Gabriela Pabón-Cartagena, MD, et al.
Published: (2020)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020)

Clinical utility of nivolumab in the treatment of advanced melanoma
by: Asmar R, et al.
Published: (2016)